PathAI’s Year in Review: Delivering on the Promise of AI-Powered Digital Pathology - Part Two
Digital pathology and AI are revolutionizing personalized medicine and fueling groundbreaking research with applications in diagnostics, drug development, clinical trials, and beyond. The era of computationally-driven scientific discovery and its clinical applications are redefining healthcare. Read Part One >>
For the second edition of our 2024: Year In Review, we spoke with PathAI scientists and commercial leaders to discuss their favorite moments and what they see as the future for our upcoming year, here is what they had to say:
Entering the Age of Digital Pathology
Digital Diagnostics - Parth Chodavadia, MD, Global Head of Commercial
“In the rapidly evolving field of digital diagnostics, we’ve reached a significant milestone with the CE marking of the AISight? Dx Image Management System for primary diagnosis. This is a testament to the reliability and clinical potential of our platform. Pathology has historically been a bottleneck in the diagnostic process, with patients often waiting for critical results due to limited resources and the complexity of manual workflows. With AISight?, we’re reducing these delays by enabling pathologists to deliver more efficient and precise assessments and by allowing institutions to collaborate in real-time across geographies and organizations.?
Our innovations and improvements—such as AISight? Marketplace with AI integrations, Guided Review, and Z-Stack Image Support—are enabling pathologists to prioritize cases and access comprehensive, actionable insights. Products such as?ArtifactDetect, TumorDetect, MET Predict for NSCLC, AIM-MASH, and AIM-IHC Breast Panel, combined with our strategic partnerships with global organizations, are empowering clinicians and researchers to accelerate the path to better outcomes for patients. AISight’s recognition as 2024 Diagnostics Innovation of the Year is a testament to the transformative impact our solutions are having. We look forward to continuing to reshape pathology workflows for the betterment of healthcare with partners across the globe.”
Empowering Precision Oncology with AI-Driven Pathology
Oncology - Ryan Leung, Head of Biopharma Product & Bahar Rahsepar, PhD, Senior Product Manager
"The launch of several powerful AI-powered pathology tools—including IHC Explore?, PathExplore? IOP (Immuno-Oncology Profiling), and PathExplore? Fibrosis—represents a leap forward in how we approach cancer research and treatment. These innovations offer researchers and clinicians deeper, more actionable insights into cancer biology. We’ve seen remarkable excitement around the launch of IHC Explore? for immunohistochemistry research. More precise biomarker discovery and quantification allows for better identification of key cancer biomarkers, which is critical for advancing immuno-oncology research. IHC Explore? tool makes it possible not only to identify biomarkers with greater accuracy but also to quantify them in a way that hasn’t been possible before. This capability is especially important in the development of antibody-drug conjugates (ADCs), where the precise identification and quantification of tumor-specific biomarkers are essential for scaling the next generation of cancer therapeutics."
"PathExplore? continues to be a cornerstone of our AI-driven pathology platform. This year, we’ve expanded its capabilities in tumor microenvironment (TME) analysis and fibrotic microenvironment assessment. By transforming pathology images into quantifiable, high-resolution data, we’re uncovering new insights into the prognostic factors that influence cancer progression. These advancements are key for identifying new biomarkers, improving treatment strategies, and accelerating drug development. Through our platform, we’re turning unstructured images into structured, actionable insights, allowing researchers to leverage multimodal data—integrating histopathology with genomic and clinical data—for more comprehensive and precise analyses of cancer biology. Moreover, our commitment to advancing the field is reinforced by strategic partnerships to our expand access to pathology-centric real-world data. These collaborations provide us with richer, more diverse data to enhance our AI models and offer more robust insights. As we continue to develop these tools, our goal is clear: to empower researchers and clinicians to make data-driven decisions that can accelerate the fight against cancer."
Validating AI and driving precision pathology/medicine for drug development in MASH & IBD
Inflammation & Immunology - Christina Jayson, Ph.D., Associate Director of Product
“This year we’ve generated evidence that shows how AI-pathology brings precision insights to metabolic and inflammatory diseases, particularly in the GI space. These insights demonstrate growing confidence in our AI-powered pathology tools to revolutionize research and drug development.
For example, ur groundbreaking publications in Nature Medicine demonstrated the potential of AIM-MASH for automating clinical trial endpoints and the validation of AI-based pathology tools for scoring metabolic dysfunction-associated steatohepatitis (MASH) biopsies to bring accuracy and reproducibility where variability is rampant. We’ve also seen growing excitement in MASH and liver diseases around the potential to characterize and capture disease progression with Liver Explore?, helping clinicians and drug developers better understand these conditions from a research perspective and apply their learnings for clinical research and clinical trials. Similarly, we’ve explored the identification of signatures prognostic of therapeutic response with IBD Explore?, highlighting opportunities for AI-powered pathology in patient stratification or therapy selection in a space where durable remission is challenging. Through our partnership with the Crohn's & Colitis Foundation, we’re also unlocking new insights with AIM-HI UC and IBD Explore? from Real-World Data (RWD) to improve the lives of patients suffering from Ulcerative Colitis and Crohn’s Disease. Meanwhile, for Celiac Disease, our Scientific Reports publication highlights our deepening expertise as we apply our AI tools to automate cell type and tissue area classification, improving diagnostic research and holding the potential to transform therapeutic efficacy assessment and treatment strategies for these complex conditions.?
What's even more exciting is that through our Biopharma Lab, we’re supporting more clinical trials than ever before. In our strategic partnership with Clario, we’re enabling streamlined clinical trial pathology services across GI indications. Together, our end-to-end services enable these innovations in AI pathology to play a crucial role in bringing precision pathology to drug development and driving better patient outcomes in IBD, Celiac Disease, liver diseases, and beyond.”
We look forward to another year of innovation in 2025 - Thank you for joining us in our mission to improve patient outcomes with AI-powered pathology!
AISight? is for Research Use Only in the US; AISight? Dx is CE-IVD marked in the EEA, UK, and Switzerland.PathExplore?, PathExplore? IOP, IHC Explore?, AIM-MASH, AIM-IHC Breast Panel, MET Predict, IBD Explore? are for Research Use Only. Not for use in diagnostic procedures.
Associate Director, Product Marketing @ PathAI | Pathology Transformed
2 个月Happy New Year x2 to the PathAI team!